|
福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.65 (2019) >
このアイテムの引用には次の識別子を使用してください:
http://ir.fmu.ac.jp/dspace/handle/123456789/776
|
| タイトル: | Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer |
| 著者: | Hayase, Suguru
Yamada, Leo
Ujiie, Daisuke
Nirei, Azuma
Tada, Takeshi
Hanayama, Hiroyuki
Monma, Tomoyuki
Saze, Zenichiro
Ohki, Shinji
Kono, Koji |
| 学内所属: | 消化管外科学講座 |
| 誌名/書名: | Fukushima Journal of Medical Science |
| 巻: | 65 |
| 号: | 1 |
| 開始ページ: | 6 |
| 終了ページ: | 12 |
| 発行日: | 2019年 |
| 抄録: | Introduction Recently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric cancer in our institution. Patients and Methods The subjects were 11 patients with unresectable and recurrent gastric cancer who received RAM plus PTX as a second- or later-line treatment at our hospital between June 2015 and September 2017, after the failure of previously-attempted treatments. We assessed the efficacy and safety of RAM plus PTX, and also compared them between patients aged <75 years (n=6) and those aged ≥75 (n=5), by performing a retrospective analysis based on the data obtained from daily clinical practice for gastric cancer treatment. Results Objective tumor response was observed in one of the 11 patients (9.1%) with partial response, and disease control was seen in the remaining 10 (90.9%). The median overall survival (OS) and progression-free survival (PFS) of the patients were 20.8 months (95% CI 7.8-NA (not applicable)) and 11.3 months (95% CI 6.5-NA), respectively. There were no serious adverse events. The median OS for the <75 years group and ≥75 years group was NA (due to short follow-up period) and 20.8 months (p = 0.336), respectively, and their respective median PFS rates were 9.4 and 11.3 months (p = 0.492). The difference of rate of adverse events was not significant between the two age groups in the present study, though the number of adverse events was not sufficient. Conclusion The results of the present study suggest that the combination chemotherapy of RAM and PTX was effective in unresectable and recurrent gastric cancer patients as a second- or later-line therapy, and has been shown to be safe and feasible in elderly patients. |
| 出版者: | The Fukushima Society of Medical Science |
| 出版者（異表記）: | 福島医学会 |
| 本文の言語: | eng |
| このページのURI: | http://ir.fmu.ac.jp/dspace/handle/123456789/776 |
| 本文URL: | http://ir.fmu.ac.jp/dspace/bitstream/123456789/776/1/FksmJMedSci_65_p6.pdf |
| ISSN: | 0016-2590
2185-4610 |
| DOI: | 10.5387/fms.2018-12 |
| PubMed番号: | 30996218 |
| 関連ページ: | https://doi.org/10.5387/fms.2018-12 |
| 権利情報: | © 2019 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. |
| 権利情報: | https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| 出現コレクション: | Vol.65 (2019)
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|
